Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study is important to demonstrate if single agent activity is noted for patients with
thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens
the door to evaluate other combination of drugs with imatinib in thymic tumors.